07:00 , Oct 26, 2015 |  BC Week In Review  |  Company News

Commonwealth Laboratories, Quest Diagnostics sales and marketing update

Commonwealth’s IBSchek is now available through Quest. The ELISA-based blood test detects antibodies against cytolethal distending toxin B (CdtB) and vinculin (VCL) within 24 hours to diagnose irritable bowel syndrome (IBS). Commonwealth...
07:00 , Sep 7, 2015 |  BC Week In Review  |  Company News

Commonwealth Laboratories, Valeant Pharmaceuticals deal

Valeant will acquire Commonwealth’s U.S. and Canadian business for an undisclosed upfront payment. Commonwealth is also eligible for undisclosed sales milestones. The deal includes IBSchek, an ELISA-based blood test to diagnose irritable bowel syndrome...
07:00 , Jul 13, 2015 |  BC Week In Review  |  Company News

Commonwealth Laboratories sales and marketing update

Commonwealth launched its IBSchek ELISA-based blood test to diagnose irritable bowel syndrome (IBS). The laboratory-developed test (LDT) detects antibodies against cytolethal distending toxin B (CdtB) and vinculin (VCL) within 24 hours. Commonwealth...